A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

NCT06765317 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma (DLBCL)
High Grade B Cell Lymphoma

Interventions

DRUG: Glofitamab
DRUG: Polatuzumab
DRUG: Rituximab
DRUG: Cyclophosphamide
DRUG: Doxorubicin
DRUG: Obinutuzumab:

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]